Details of the Drug

General Information of Drug (ID: DMK2RIB)

Drug Name
GTB-3550
Synonyms OXS-3550
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Phase 1/2 [1]
Mast cell leukaemia 2A21.00 Phase 1/2 [1]
Myelodysplastic syndrome 2A37 Phase 1/2 [1]
Systemic mastocytosis 2A21.0 Phase 1/2 [1]
Drug Type
Recombinant protein
Cross-matching ID
UNII
E5GE91Q5FX
DrugBank ID
DB18494
TTD ID
D9O7GC
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin gamma Fc receptor III (FCGR3) TT7KTSR FCG3A_HUMAN ; FCG3B_HUMAN Inhibitor [2]
Myeloid cell surface antigen CD33 (CD33) TTJVYO3 CD33_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myelogenous leukaemia
ICD Disease Classification 2A41
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myeloid cell surface antigen CD33 (CD33) DTT CD33 5.37E-13 0.58 1.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of GT Biopharma.